All In Biotech

Drug Trial Radar · NCT07178249

Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD

A Phase I/II Clinical Study Evaluating the Safety and Preliminary Efficacy of EXG202 in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 16, 2025

Primary completion

Feb 28, 2028

Study completion Dec 30, 2032

Sponsor

Lead sponsor
Guangzhou Jiayin Biotech LtdIndustry
Sponsor type
Industry
First posted
Sep 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

VEGF inhibitors (anti-VEGF),such as aflibercept has been shown to be safe and effective for treating nAMD and have demonstrated improvement in vision. However, anti-VEGF therapy is administered frequently via intravitreal injection and can be a significant burden to the patients. EXG 202 is a recombinant adeno-associated virus (rAAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein. The long-term, stable delivery of this therapeutic protein following a 1 time gene therapy treatment for nAMD could potentially reduce the treatment burden of currently available therapies while maintaining vision with a favorable benefit.

Conditions

  • Wet Age-related Macular Degeneration

Interventions

  • EXG202 injectionBiological

    EXG202 injection is a gene therapy product for the treatment of wet (neovascular) Age-related Macular Degeneration(wAMD) with a single intravitreal injection and administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability after EXG202 injectionTime frame: Up to 52 weeks after treatment
  2. Preliminary Efficancy after EXG202 injectionTime frame: Up to 52 weeks after treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.